Table 9.

Disease outcomes by series in phase III adjuvant chemoradiotherapy trials in rectal cancer.

Disease outcomes (5-yr)	German trial*			US GI Intergroup postop
	Preop CRT	Postop CRT	P value	INT 0114†	INT 0144‡
No. patients/series	397	384		1,695	1,917
Overall survival	76%	74%	.80	64%	68%–71%
Disease-free survival	68%	65%	.32	54%	57%–62%
Local relapse
Total group	6%	13%	.006	14%	4.6%–8%‡
T1-2N1-2; T3N0-2‡	–	–		–	3%–5%‡
Intermediate risk†	–	–		–	–
T1-2N1				6%
T3N0				8%
Distant metastasis	36%	38%	.84	NA	NA

^*Modified from Sauer et al³⁴

^†Modified from Tepper et al²¹ and Gunderson et al¹²

^‡Modified from Smalley et al⁵³

Local relapse data are absolute not 5-year actuarial; the T1-2N1-2 plus T3N0-2 data are only for patients with low anterior resection.

Abbreviations: CRT, chemoradiotherapy; NA, not available; Postop, postoperative; Preop, preoperative.